Research on the assesment of the effect of chemotherapy in malignant gliomas using genome DNA micioanay

胶质母细胞瘤是一种快速生长的肿瘤，占所有原发性胶质瘤的50%以上。癌基因的扩增和抑癌基因的缺失经常影响肿瘤的进展。因此，本研究的目的是对单个胶质母细胞瘤的基因畸变进行全面分析。使用基因组DNA微阵列（GenoSensor Array^<TM>300），点样287个靶基因，分析11个不同高级别胶质瘤的切除组织。基因畸变的平均数为9.0/例（WHO III级）和13.3/例（WHO IV级）。EGFR是该系列中最常见的扩增基因（4/11例），EGFR、SAS/CDK 4和AKT 1也检测到高水平扩增。在11例中有6例（54.5%）观察到高频率的EGFR基因，包括FGFR 2、MTAP和DMBT 1。9例中有5例的基因畸变与经典的原发性胶质母细胞瘤通路相匹配。我们认为GenoSensorArray^300<TM>基因组DNA微阵列是一种综合鉴定胶质母细胞中扩增和缺失基因的有效方法

Glioblastoma is a rapidly growing tumor that accounts for more than 50% of all primary gliomas. Amplification of oncogenes and deletion of tumor suppressor genes frequently affects tumor progression. Thus, the goal of this study was to conduct a comprehensive analysis of gene aberrations of individual glioblastomas. A genome DNA microarray (GenoSensor Array^<TM> 300), spotted with 287 target genes, was used to analyze resected tissue from 11 different high-grade gliomas. The average number of gene aberrations was 9.0 per case (WHO grade III) and 13.3 per case (WHO grade IV). EGFR was the most frequent amplified gene in this series (4/11 cases), and high-level amplification was also detected for EGFR, SAS/CDK4 and AKT1. Deleted genes with high frequency were observed in 6 of 11 cases (54.5%) and included FGFR2, MTAP and DMBT1. The detected gene aberrations were matched to the classical primary glioblastoma pathway in 5 of 9 cases. We conclude that the GenoSensor Array^<TM> 300 genomic DNA microarray is a useful method for the comprehensive identification of amplified and deleted genes in glioblasto